Financial reports
ARS
2023 FY
Annual report to shareholders
28 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
9 May 23
10-K
2022 FY
Annual report
30 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
4 Aug 22
10-Q
2022 Q1
Quarterly report
5 May 22
10-K/A
2021 FY
Annual report (amended)
21 Apr 22
Current reports
8-K
Departure of Directors or Certain Officers
17 Apr 24
8-K
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
29 Feb 24
8-K
Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
2 Nov 23
8-K
Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
14 Aug 23
8-K
Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors
11 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 23
8-K
Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
9 May 23
8-K
Departure of Directors or Certain Officers
1 May 23
8-K
Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
30 Mar 23
8-K
Results of Operations and Financial Condition
6 Feb 23
Registration and prospectus
S-8
Registration of securities for employees
13 Jul 23
S-8
Registration of securities for employees
17 Oct 22
424B5
Prospectus supplement for primary offering
26 Sep 22
425
Business combination disclosure
2 Sep 22
425
Business combination disclosure
15 Aug 22
425
Business combination disclosure
10 Aug 22
424B3
Prospectus supplement
29 Jul 22
425
Business combination disclosure
6 Jul 22
S-4
Registration of securities issued in business combination transactions
15 Jun 22
Proxies
DEFA14A
Additional proxy soliciting materials
1 May 23
DEF 14A
Definitive proxy
1 May 23
DEF 14A
Definitive proxy
28 Apr 21
DEFA14A
Additional proxy soliciting materials
28 Apr 21
DEF 14A
Definitive proxy
29 Apr 20
DEF 14A
Definitive proxy
30 Apr 19
DEFA14A
Additional proxy soliciting materials
24 Apr 18
DEF 14A
Definitive proxy
24 Apr 18
DEFA14A
Additional proxy soliciting materials
9 May 17
DEFA14A
Additional proxy soliciting materials
5 May 17
Other
EFFECT
Notice of effectiveness
29 Jul 22
CORRESP
Correspondence with SEC
26 Jul 22
EFFECT
Notice of effectiveness
5 May 21
CORRESP
Correspondence with SEC
30 Apr 21
UPLOAD
Letter from SEC
6 Apr 21
EFFECT
Notice of effectiveness
8 Feb 21
CORRESP
Correspondence with SEC
3 Feb 21
UPLOAD
Letter from SEC
3 Feb 21
EFFECT
Notice of effectiveness
28 Aug 20
CORRESP
Correspondence with SEC
25 Aug 20